While the Buy rating suggests continued confidence in Sonnet BioTherapeutics' long-term prospects, the significant reduction in the price target could indicate concerns about near-term challenges or valuation adjustments. This mixed signal might lead to short-term market uncertainty for SONN, potentially causing volatility in its stock price.